TG Therapeutics, Inc. (TGTX) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $49.78, but acceptable to hold if already in. Reasons: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain.
TG Therapeutics is a commercial-stage biotech with one FDA-approved product, BRIUMVI (ublituximab-xiiy) for relapsing forms of MS, commercially launched in the U.S. in January 2023. Ex-U.S. rights are licensed to Neuraxpharm (deal up to $645M plus tiered royalties up to 30%).... Read more
Hold if already holding. Not a fresh buy at $49.78, but acceptable to hold if already in. Reasons: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — TG Therapeutics, Inc.
Latest news
- NEWS TG Therapeutics (TGTX) Stock Momentum | Q4 2025: Earnings Fall Short - Margin Expansion - Newser — Newser neutral
- NEWS TG Therapeutics (TGTX) Q1 earnings lag estimates - MSN — MSN negative
- NEWS Tg therapeutics stock hits 52-week high at 41.24 USD By Investing.com - Investing.com India — Investing.com India positive
- NEWS Earnings Flash (TGTX) TG Therapeutics, Inc. Reports Q1 Revenue $204.9M - marketscreener.com — marketscreener.com neutral
- NEWS TG Therapeutics (TGTX) Q1 Earnings Lag Estimates - Yahoo Finance — Yahoo Finance negative
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRIUMVI10-K Item 1: 'TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis'
- HIGHSuppliersole-source supply chain10-K Item 1A: 'The third parties upon whom we rely for the supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance, drug product, and other materials used in our drug candidates are our sole source of supply'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $49.78, but acceptable to hold if already in. Reasons: Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $49.59 (-0.4%), stop $46.34 (−7.4%), A.R:R -1.1:1. Score 6.3/10, moderate confidence.
Take-profit target: $49.59 (-0.5% upside). Target $49.59 (-0.4%), stop $46.34 (−7.4%), A.R:R -1.1:1. Stop-loss: $46.34.
Concentration risk — Product: BRIUMVI; Concentration risk — Supplier: sole-source supply chain; Analyst target reached - limited upside remaining.
TG Therapeutics, Inc. trades at a P/E of 17.3 (forward 17.2). TrendMatrix value score: 5.4/10. Verdict: Hold.
15 analysts cover TGTX with a consensus score of 3.9/5. Average price target: $48.
What does TG Therapeutics, Inc. do?TG Therapeutics is a commercial-stage biotech with one FDA-approved product, BRIUMVI (ublituximab-xiiy) for relapsing...
TG Therapeutics is a commercial-stage biotech with one FDA-approved product, BRIUMVI (ublituximab-xiiy) for relapsing forms of MS, commercially launched in the U.S. in January 2023. Ex-U.S. rights are licensed to Neuraxpharm (deal up to $645M plus tiered royalties up to 30%). Pipeline includes subcutaneous ublituximab (Phase 3) and azer-cel CAR-T (Phase 1).